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Warfarin Genotyping Reduces Hospitalization Rates
Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study)
Robert S. Epstein, MD, MS,* Thomas P. Moyer, PHD,† Ronald E. Aubert, PHD,*
Dennis J. O’Kane, PHD,† Fang Xia, PHD,* Robert R. Verbrugge, PHD,* Brian F. Gage, MD, MS,‡
J. Russell Teagarden, DMH, RPH*
Franklin Lakes, New Jersey; Rochester, Minnesota; and St. Louis, Missouri
Objectives This study was designed to determine whether genotype testing for patients initiating warfarin treatment will
reduce the incidence of hospitalizations, including those due to bleeding or thromboembolism.
Background Genotypic variations in CYP2C9 and VKORC1 have been shown to predict warfarin dosing, but no large-
scale studies have prospectively evaluated the clinical effectiveness of genotyping in naturalistic settings
across the U.S.
Methods This national, prospective, comparative effectiveness study compared the 6-month incidence of hospitalization in
patients receiving warfarin genotyping (n  896) versus a matched historical control group (n  2,688). To eval-
uate for temporal changes in the outcomes of warfarin treatment, a secondary analysis compared outcomes for
2 external control groups drawn from the same 2 time periods.
Results Compared with the historical control group, the genotyped cohort had 31% fewer hospitalizations overall (ad-
justed hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.58 to 0.82, p  0.001) and 28% fewer hospital-
izations for bleeding or thromboembolism (HR: 0.72, 95% CI: 0.53 to 0.97, p  0.029) during the 6-month
follow-up period. Findings from a per-protocol analysis were even stronger: 33% lower risk of all-cause hospital-
ization (HR: 0.67, 95% CI: 0.55 to 0.81, p  0.001) and 43% lower risk of hospitalization for bleeding or throm-
boembolism (HR: 0.57, 95% CI: 0.39 to 0.83, p  0.003) in patients who were genotyped. During the same pe-
riod, there was no difference in outcomes between the 2 external control groups.
Conclusions Warfarin genotyping reduced the risk of hospitalization in outpatients initiating warfarin. (The Clinical and
Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
[MHSMayoWarf1]; NCT00830570) (J Am Coll Cardiol 2010;55:2804–12) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.009f
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sarfarin is an anticoagulant that has been the standard of care
or more than 50 years to prevent and treat thromboemboli.
pproximately 2 million Americans initiate warfarin therapy
nnually (1), and currently there are no oral alternatives
vailable in the U.S. Because of the overriding need for effective
nticoagulation, warfarin remains a commonly used drug in
pite of the significant morbidity and mortality associated with
ts use. It is the second leading drug-related reason for
mergency department visits (2) and the most often cited
eason for drug-related mortality (3). Methods to improve the
afety and effectiveness of warfarin therapy are urgently needed.
rom the *Department of Medical and Analytical Affairs, Medco Health Solutions,
nc., Franklin Lakes, New Jersey; †Department of Laboratory Medicine and Pathol-
gy, Mayo Clinic, Rochester, Minnesota; and the ‡Department of Internal Medicine,
ashington University, St. Louis, Missouri. Supported by Mayo Clinic Center for
ndividualized Medicine and Medco Health Solutions.(
Manuscript received February 15, 2010; revised manuscript received March 9,
010, accepted March 11, 2010.Reaching a stable, therapeutically effective dose of war-
arin is difficult because it is dependent on multiple factors,
ncluding age, weight, diet, concurrent medications, and
enetic variability in drug response (4,5). Most drug-related
See page 2813
dverse events are due to problems in establishing the
ffective dose; it can take many weeks to evaluate, adjust,
nd stabilize the dose for an individual patient. During the
ose adjustment phase, patients are at serious risk for
emorrhage or thrombosis (1,5). Event rates for bleeding or
hromboembolism range as high as 16.5% and 25% during
he first 6 months of warfarin treatment in usual care
ettings (6,7).
Over the past decade, variations in 2 genes have been
hown to predict individual response to warfarin dosing
8–11). One gene determines the activity of the hepatic
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June 22, 2010:2804–12 Warfarin Genotyping Reduces Hospitalizationsoenzyme cytochrome P450 2C9 (CYP2C9), which plays a
ignificant role in metabolizing S-war-farin into its inactive form
12). The other gene, VKORC1 (VKOR complex subunit 1),
etermines the activity of vitamin K epoxide reductase
VKOR), an enzyme that produces the active form of vitamin
necessary for blood clotting (13). The CYP2C9 and
KORC1 polymorphisms account for more than one-third of
he variance associated with stable therapeutic dosing
8,9,14,15). Simultaneous evaluation of a patient’s deoxyribo-
ucleic acid for allelic variations in these 2 genes is known as
arfarin sensitivity genotyping.
Laboratory tests for CYP2C9 and VKORC1 polymor-
hisms are commercially available, but their use in warfarin
reatment has been very limited. Without data substantiat-
ng the clinical utility of warfarin genotyping, many clini-
ians have been reluctant to adopt warfarin sensitivity
esting in standard practice (12,16,17). A few small studies
ave evaluated the impact of warfarin genotyping on clinical
vents (such as bleeding or thrombosis), and they have
hown mixed results (17–21). No published studies to date
ave been powered adequately to evaluate the impact of
enotyping on clinical outcomes, although a few studies are
nderway to address this.
Our study is the first national, prospective, comparative
ffectiveness study of the impact of warfarin sensitivity
enotyping in patients who initiate warfarin therapy in typical
ractice settings. The study was designed to evaluate the
mpact of genotype testing on hospitalization rates in the first
months of warfarin treatment, comparing genotyping with
sual care.
ethods
tudy design. We enrolled patients in naturalistic settings
ith minimal protocol-based constraints on patients or
hysicians that might limit its external validity. To achieve
his objective, we employed a quasi-experimental design,
hich is a well-established means of evaluating an interven-
ion in an environment with significant natural variability in
linical practices (22–24). This design strategy enabled us to
nroll a broader and more representative range of providers
nd patients than is typical in randomized, controlled
linical trials.
For the primary intervention, we invited patients initiat-
ng outpatient warfarin treatment to undergo free genotype
esting with their physician’s approval. These patients were
rawn from the member populations of prescription benefit
lans that agreed to participate in the study. Medical claims
or these patients were tracked for the occurrence of
ospitalizations during the 6 months following the start of
arfarin treatment (the date of the index prescription).
ospitalization rates for these patients were compared with
ates for a historical control group of similar patients who
ere new to warfarin treatment, but began treatment during
he preceding year. The principal comparison was the
ifference in event-free time during the first 6 months after ireatment onset, comparing out-
omes for the intervention group
ith the historical controls.
To quantify potential tempo-
al trends over the same 2 time
eriods, we constructed 2 exter-
al control groups using similar
riteria: a cohort that began war-
arin therapy during the same
ime period as the intervention group (external concurrent
ontrols), and a cohort that began treatment during the
rior year (external historical controls). Hospitalization rates
or the 2 external control groups were compared to deter-
ine whether changes in the intervention group could be
ttributed to temporal changes in general clinical practice.
tudy sample. Patients in all of the study groups were
embers of prescription benefit plans managed by Medco
or a representative range of benefit plan sponsors (employ-
rs, health plans, and government organizations) with plan
embership spanning the U.S. The plans included health
aintenance organizations, preferred provider organiza-
ions, and traditional fee-for-service plans.
Entry criteria for the intervention group were kept to a
inimum. Beginning in July 2007, any adult from partici-
ating plans who was 40 to 75 years of age and initiated
utpatient warfarin therapy was eligible for study entry.
atients were excluded if they had a prescription for
arfarin in the previous 180 days, had a hospitalization
onger than 7 days before starting warfarin, were prescribed
hort-term use of warfarin, had a prior history of genetic
esting for warfarin, had a known hypersensitivity to war-
arin, or had no known telephone number to initiate contact
or study participation. Patients had to be continuously
ligible for prescription benefits during the 6 months before
o the index prescription to ensure accurate evaluation of
heir prior medication use, medical conditions, and lack of
rior warfarin use. The same inclusion and exclusion criteria
ere applied to patients in all of the control groups.
articipants in the intervention group had to supply in-
ormed consent for the study, as did their treating physician.
A total of 29 benefit plan sponsors agreed to have their
embers identified for participation in the intervention
roup. For these original plan sponsors, 1,635 patients were
nitially enrolled and genotyped as part of the intervention
roup. By the time the study closed, the requisite medical
laims data for longitudinal outcomes evaluation were avail-
ble for 23 plans, leaving a total of 896 evaluable genotyped
atients in the intervention group; all of these patients were
ncluded in the study analysis. Patients in the historical
ontrol group were drawn from the same 23 plans, and they
ere matched in age and sex on a 3:1 basis with patients in
he intervention group. The external control groups were
erived from 56 plans unrelated to these 23 plans and were
imilarly matched for age and sex on a 3:1 basis with the
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
INR  international
normalized ratio
PP  per-protocolntervention group.
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Warfarin Genotyping Reduces Hospitalization June 22, 2010:2804–12ntervention. Utilizing real-time pharmacy claims data, we
dentified candidates for the intervention on the day their
arfarin treatment was initiated on an outpatient basis.
tudy candidates and their physicians were contacted to
ecure their consent to participate in the study; all were
dvised that their participation was voluntary. Terms of
articipation were defined in the study protocol, which had
een reviewed and approved by the Mayo Clinic Institu-
ional Review Board and an independent, external Institu-
ional Review Board contracted by Medco, and recorded on
linicaltrials.gov (NCT00830570).
The intervention comprised 2 primary steps: 1) gathering
he patient’s deoxyribonucleic acid for CYP2C9 and VKORC1
enotyping; and 2) delivering the results in a report with
nterpretation to the physician. To approximate conditions of
ypical clinical practice, and consistent with the product label
uring the study period, there were no mandated interventions
ollowing delivery of the laboratory report. Physicians provided
sual care supplemented by testing for genetic variations that
ould affect the patient’s sensitivity to warfarin. They had the
ption to adjust warfarin dosing based on the patient’s geno-
ype test results, but their treatment practices were uncon-
trained by study protocol.
enotype testing. During the first half of study recruit-
ent, a Medco-affiliated nurse visited the patient’s home to
ollect a blood sample for genetic testing. After the Mayo
linic confirmed the reproducibility of test results between
lood and buccal swab samples, we mailed buccal swabs to
ncrease convenience and reduce study costs. After procur-
ng patients’ informed consent, the test samples were sent to
he Mayo Clinic for genotype testing.
The CYP2C9 and VKORC1 tests were performed by the
ayo Clinic on a Luminex platform using reagents ac-
uired from Luminex Molecular Diagnostics (Austin,
exas). These tests were approved for use in clinical practice
s in-house developed tests as authorized by the Clinical
aboratory Improvement Act, 42 CFR 493.
henotype Characteristics of Intervention Group PatientsTable 1 Phenotype Characteristics of Intervention Group Patien
Warfarin Sensitivity
Genotype Combination
VKORC1 CYP2C9
Very high A/A
G/A
*1/*3, *2/*2, *2/*3, *3/*3
*3/*3
High A/A
G/A
G/G
*1/*2
*2/*3
*3/*3
Moderate A/A
G/A
G/G
*1/*1
*1/*2, *1/*3, *2/*2
*2/*3
Mild G/G *1/*2, *1/*3, *2/*2
Normal G/A *1/*1
Less than normal G/G *1/*1
Total
alues are n (%). Genotype is defined by the combination of measured allelic variations in CYP2C9
t appeared in laboratory report is provided in online supplement (Online Table 2).
INR  international normalized ratio.During clinical validation of the test, CYP2C9 *2 and *3
ariants and VKORC1 A/A, G/A, and G/G variants were
etectable in 98% of cases evaluated (11). Although other
ariants of CYP2C9 and VKORC1 may be present, these
lleles (all of which are identified by the Luminex Molecular
iagnostics assay) are the most important for determining
ose (9), and they are the only ones considered by the U.S.
ood and Drug Administration to be valid biomarkers for
arfarin dosing (25).
The report to the physician included genotype and
redicted phenotype. The phenotype represents the patient’s
ikely sensitivity to warfarin based on genotype (Table 1). The
hysician report also included patient-specific clinical con-
iderations and some general information about potential
rug-drug interactions with warfarin (sample report shown
n Online Tables 1 and 2).
utcome measures. The primary study end point for all
roups was the incident hospitalization rate (measured as
vent-free time) during the 6 months following the start of
utpatient warfarin treatment. The event-free time is the
umber of days between warfarin initiation and the first
ospitalization due to any cause or the first hospitalization
ue to bleeding or thromboembolism. Events due to bleed-
ng or thromboembolism were identified from medical
laims using International Classification of Diseases-Ninth
evision codes that have been shown to have a high degree
f validity as measures for cardiovascular adverse events
26–28). Baseline characteristics for patients in all groups
ere derived from benefit eligibility and drug utilization
atabases maintained by Medco, and from medical utiliza-
ion data supplied by participating plans.
tatistical analysis. Using chi-square tests for categorical
ariables and t tests for continuous variables, baseline
haracteristics were compared between the intervention and
istorical control groups and between the 2 external control
roups. Unadjusted comparisons of the primary outcome
Prevalence Clinical Considerations*
23 (2.6%) Dose decrease and frequent INR monitoring
36 (4.0%) Dose decrease and frequent INR monitoring
238 (26.6%) Dose decrease and frequent INR monitoring
109 (12.2%) Frequent INR monitoring
262 (29.2%) Likely to experience normal response to warfarin
228 (25.4%) Dose increase may be required to maintain optimal INR
896 (100%)
ORC1. Phenotype is the expected warfarin sensitivity based on genotype. *Complete wording asts
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June 22, 2010:2804–12 Warfarin Genotyping Reduces Hospitalizationeasures (incident hospitalization rates) were conducted
sing Kaplan-Meier methods and log-rank tests.
To address potential selection bias, we used propensity
cores to control for factors that may be associated with
atients’ likelihood of participating in genotype testing.
sing a logistic regression model, we developed a propensity
core to measure the likelihood of being tested. The model
ncluded age, prescription medications known to interact
ith warfarin metabolism (amiodarone, statins, sulfame-
hoxazole, fluconazole), other commonly used medications
nonsteroidal anti-inflammatory drugs, clopidogrel, cortico-
teroids), and history of hospitalization for bleeding or
hromboembolism in the 6 months before initiating warfa-
in. The propensity analysis found very little difference
etween patients in the intervention and historical control
roups based on these parameters.
Adjusted comparisons were based on multivariate Cox
roportional hazards models, controlling for primary indi-
ations for warfarin treatment (atrial fibrillation, pulmonary
mbolism, deep vein thrombosis), selected comorbid condi-
ions (gastrointestinal bleed, hypertension, diabetes), and pro-
ensity score quintiles. We analyzed the data using an
ntention-to-treat analysis whereby all hospitalizations follow-
ng the start of warfarin therapy were included, even if
ospitalizations occurred before genotyping (in the interven-
ion group).
We also performed a per-protocol (PP) analysis in which
Baseline Characteristics of Study PopulationTable 2 Baseline Characteristics of Study P
Characteristic
Historical C
(n  2,6
Mean age, yrs (SD) 65.2 (8
Men 60.5%
Medications
Amiodarone* 4.0%
Statins* 14.5%
Sulfamethoxazole* 4.4%
Fluconazole* 2.4%
NSAIDs 19.6%
Clopidogrel 10.8%
Corticosteroids 12.4%
Conditions
Atrial fibrillation 40.4%
Pulmonary embolism 11.0%
Deep vein thrombosis 24.6%
GI bleed 3.6%
Hypertension 47.0%
Diabetes 15.3%
Prior hospitalizations
Any cause 54.4%
Bleeding or thromboembolism 23.6%
Age is determined as of index warfarin prescription date. Medication u
months; days’ supply may be concurrent with warfarin use. Medical c
(diabetes) or medical diagnosis per International Classification of Di
hospitalizations are identified during the prior 6 months based on med
amiodarone and sulfamethoxazole (moderate inhibitors), and statins
GI  gastrointestinal; NSAID  nonsteroidal anti-inflammatory drugnly the events occurring after genotyping were counted for batients in the intervention group. In the PP analysis, event
ates for the control groups were adjusted by randomly assign-
ng nonmeasured intervals following each patient’s first warfa-
in prescription. The distribution of these nonmeasured inter-
als matched the intervals between the first prescription and
enotype testing in the intervention group, so that early events
n the control groups were discounted to an equal degree.
esults
atients in both study groups averaged 65 years of age, and
1% were male (Table 2). The 2 groups were balanced in
revalence of primary indications for warfarin therapy (atrial
brillation, pulmonary embolism, deep vein thrombosis).
mong comorbid conditions, the prevalence of hyperten-
ion was higher in the intervention group than in the
istorical control group, but the prevalence of treated
iabetes was lower. The 2 groups were balanced with respect
o concomitant medications (including CYP2C9 inhibitors)
hat could be potential confounding variables. The groups
ere also well matched in hospitalization rates for any cause
r for bleeding or thromboembolism during the prior 6
onths. The geographic distribution of these groups was
lso balanced. Participants in each group were drawn from
9 of the 50 U.S. states.
The genotype distribution for the intervention group is
hown in Table 3, and the corresponding phenotype distri-
tion
l Intervention Group
(n  896) p Value
65.2 (8.3) 0.921
60.5% 1.000
3.2% 0.313
17.0% 0.071
5.2% 0.268
2.6% 0.803
19.9% 0.865
10.2% 0.574
13.6% 0.354
41.1% 0.709
11.8% 0.501
25.8% 0.489
4.0% 0.539
54.2% 0.001
11.6% 0.007
52.8% 0.405
24.8% 0.469
entified by any prescription for a drug or drug class during the prior 6
ns are identified during the prior 6 months using prescription claims
-Ninth Revision codes in medical claims (all other conditions). Prior
ims. *Inhibitors of CYP2C9metabolism: fluconazole (strong inhibitor),
e).opula
ontro
88)
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Warfarin Genotyping Reduces Hospitalization June 22, 2010:2804–12ad normal warfarin sensitivity, 25.4% had lower-than-
ormal sensitivity (suggesting a higher dose might be
equired), 12.2% had mild sensitivity (suggesting that more
requent monitoring might be prudent), and 33.2% had
oderate to very high sensitivity (suggesting a lower dose
ight be required, along with frequent monitoring). The
ossible dose adjustments summarized in Table 1 were
ncluded in the reports to the patients’ physicians. In total,
he genotype results for 58.6% of patients in the interven-
ion group (those with less-than-normal, moderate, high, or
ery high sensitivity) would be considered indicative of a
otentially higher or lower dose than average.
The impact of genotyping on hospitalizations is summa-
ized in Table 4. On an unadjusted basis in the intention-
o-treat analysis, patients in the intervention group showed
28% lower rate of hospitalization for any cause, compared
ith patients in the historical control group (18.5% vs.
5.5%, p 0.001). The intervention group showed a similar
7% reduction in hospitalization risk for bleeding or throm-
oembolism, compared with the historical controls (6.0%
s. 8.1%, p  0.039). In the PP analysis, the unadjusted
ifferences between the 2 groups were even larger; patients
n the intervention group showed a 31% lower rate of
ll-cause hospitalizations (14.0% vs. 20.5%, p  0.001) and
40% lower rate of hospitalizations for bleeding or throm-
oembolism (3.7% vs. 6.2%, p  0.005). By contrast, none
f the differences between the external control groups was
tatistically significant.
Adjusted hospitalization rates based on the intention-to-
reat analysis showed a similar pattern (Fig. 1). Compared
o the historical controls, patients in the genotyped group
ad 31% fewer hospitalizations overall (adjusted hazard
atio [HR]: 0.69, 95% confidence interval [CI]: 0.58 to
enotype Distribution of Intervention Group PatientsTable 3 Genotype Distribution of Intervention Group Patients
VKORC1 *1/*1 *1/*2 *1/*3
G/G 228 (25.4%) 69 (7.7%) 36 (4.0%)
A/G 262 (29.2%) 82 (9.2%) 49 (5.5%)
A/A 94 (10.5%) 26 (2.9%) 18 (2.0%)
Total 584 (65.2%) 177 (19.8%) 103 (11.5%)
alues are n (%). Data are provided for each measured allele combination.
CYP2C9  cytochrome P450 2C9; VKORC1  vitamin K epoxide reductase complex subunit 1.
nadjusted Incident Hospitalization RatesTable 4 Unadjusted Incident Hospitalization Rates
Analysis
Historical Control
(n  2,688)
Intervention Group
(n  896) p Value
Intention to treat
Any cause 25.52 18.45 0.001
Bleed or thromboembolism 8.13 5.97 0.039
Per-protocol
Any cause 20.45 14.04 0.001
Bleed or thromboembolism 6.22 3.71 0.005p
alues are Kaplan-Meier hospitalization rates per 100 patients. The p value is obtained using
og-rank test..82, p  0.001) and 28% fewer hospitalizations for
leeding or thromboembolism (HR: 0.72, 95% CI: 0.53 to
.97, p  0.029) over the 6-month follow-up period. No
ignificant differences in adjusted hospitalization rates were
bserved between the external control groups.
Adjusted hospitalization rates based on the PP analysis
Fig. 2) reveal stronger differences between the intervention
roup and the historical control group. Compared with histor-
cal controls, patients who were genotyped had 33% fewer
ospitalizations overall (HR: 0.67, 95% CI: 0.55 to 0.81,
 0.001) and 43% fewer hospitalizations for bleeding or
hromboembolism (HR: 0.57, 95% CI: 0.39 to 0.83, p 
.003). No significant differences in hospitalization rates be-
ween the external control groups were observed.
iscussion
n this comparative effectiveness study, which encompassed
housands of outpatients in practice settings across the
ountry, we found significant reductions in adverse events
or patients who were genotyped early in the course of
arfarin treatment. Compared with historical controls,
enotyped patients had 31% fewer all-cause hospitalizations
nd 28% fewer hospitalizations for bleeding or thromboem-
olism. Our findings suggest that the addition of genotyp-
ng to usual care reduces the risk of hospitalization by
pproximately 30% among patients initiating warfarin. This
eduction is consistent with a meta-analysis conducted by
ckman et al. (17), which found a trend toward a 32%
eduction in major bleeding across 3 randomized trials.
Published studies of genotype testing for warfarin have
een conducted in controlled clinical settings (18–21).
lthough the controlled nature of these studies generates
he internal validity needed to account for confounding
actors, these studies do not allow us to extrapolate that the
ndings apply to a wider array of “real-world” warfarin users
n representative patient care settings. Our study provides
nsight into the external validity of genotype testing in
arfarin therapy by evaluating the clinical outcomes of
esting for a wide range of patients treated by a wide variety
f practitioners across the U.S.
Given the nature of our study design, our findings have
pplicability to a wide range of outpatients. We intention-
lly imposed few inclusion or exclusion criteria on partici-
CYP2C9
*2/*2 *2/*3 *3/*3 Total
4 (0.4%) 5 (0.6%) 2 (0.2%) 344 (38.4%)
8 (0.9%) 8 (0.9%) 1 (0.1%) 410 (45.8%)
1 (0.1%) 2 (0.2%) 1 (0.1%) 142 (15.8%)
13 (1.5%) 15 (1.7%) 4 (0.4%) 896 (100.0%)ants in the study. As a result, participants represented a
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June 22, 2010:2804–12 Warfarin Genotyping Reduces Hospitalizationroad range of geographic regions, comorbid conditions,
oncomitant medications, treatment indications, and health
enefit plans. However, our results may not generalize to
ther populations, such as inpatients who often have more
ocused care.
Physicians in this study were diverse in geographic
istribution, practice settings, and practitioner types. In the
ntervention group, 29.4% of physicians were cardiovascular
pecialists, 49.1% were in primary care, and the remainder
n a mix of other specialties. The distribution for the
istorical controls was very similar (29.6% cardiovascular,
9.1% primary care), making it unlikely that differences in
ractitioner types or practice settings account for the ob-
erved differences in outcomes. It is also worth noting that
5.0% of the contacted physicians agreed to order the
enotype tests for their patients—a very high response rate,
hich reduces the risk of self-selection bias.
Although our study design did not include direct moni-
oring of treatment changes by physicians following receipt
f the genotype data, pharmacy claims suggest that they
esponded to the information with dosage changes that
eflect the reports (Table 5). For patients with moderate to
Figure 1 Adjusted Hospitalization Rates: Intention to Treat Ana
The figure shows the hospitalization rate for patients in each study group during the 6
events due to bleeding or thromboembolism. CI  confidence interval; HC  histoery high sensitivity to warfarin, new prescriptions showed a cecrease in dose during the 21 days following receipt of the
aboratory results; the size of the decrease was proportional
o the level of sensitivity. Similarly, patients with less-than-
ormal sensitivity showed an increase in dose during the 21
ays following receipt of the laboratory results.
Several weeks often elapsed between therapy initiation
nd delivery of the genotype results to the physician; the
nterval ranged from 11 to 60 days, with a median of 32
ays. The interval reflected several factors, including time to
eceive the order from the treating provider, obtain consent
rom the patient, collect biological samples, and return
amples to the laboratory. We found a progressive reduction
n risk the closer genotyping was to warfarin initiation.
nadjusted hospitalization rates for bleeding or thrombo-
mbolism were 5.32%, 5.47%, 6.34%, and 6.76%, based on
uartiles of time to genotype (quartile means: 22, 29, 37,
nd 48 days, respectively). This suggests that genotyping
nformation is helpful whenever it is received during the first
months of treatment, but outcomes improve the earlier the
est results can be provided.
Because we did not randomize patients to intervention
nd control groups, unmeasured differences in baseline
period following initiation of warfarin treatment. (A) Events due to any cause; (B)
ontrol; HR  hazard ratio; IG  intervention group.lysis
-month
rical characteristics (e.g., body mass index, cigarette smoking,
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onfound the results. To minimize this risk, we drew the
ntervention and historical control groups from the same set
f employers and health plans, thus enrolling patients with
imilar jobs, socioeconomic status, insurance coverage, and
eography. Additionally, we noted few differences between
Figure 2 Adjusted Hospitalization Rates: Per-Protocol Analysis
The figure shows the hospitalization rate for patients in each study group during th
that occurred after genotyping (intervention group) or the events for measured inte
thromboembolism. Abbreviations as in Figure 1.
arfarin Dosage Changes Following GenotypingTable 5 Warfarin Dosage Changes Following Genotyping
Warfarin
Sensitivity
Patients
n (%)
Weekly Dose Change
(mg)* p Value
Very high 10 (2.4%) –17.33 (4.54) 0.001
High 17 (4.0%) –10.14 (3.18) 0.040
Moderate 106 (25.0%) –3.65 (1.56) 0.003
Mild 49 (11.6%) 3.21 (3.41) 0.206
Normal 119 (28.1%) 1.10 (1.40) 0.496
Less than normal 123 (29.0%) 6.65 (1.98) 0.0001
Total 424
or patients who had a new prescription filled within 21 days of genotype testing (n  424), the
able shows the difference between the average weekly dose for the new prescription and thew
verage weekly dose for the index warfarin prescription. The p value is based on paired t test.
Values are mean (SE).ur intervention and control groups in prevalence of comor-
id conditions, treatment indications, or prior hospitaliza-
ions, and all of these variables were controlled for in the
ox proportional hazards models. Although the study
esign did not include randomization, it effectively adjusted
or major confounding factors through multiple regressions,
ropensity scores, and balancing of patient characteristics
Table 2).
It is possible that physicians in the intervention group
ere aware of being enrolled in a study and were thus more
igilant in their care, as is frequently the case in controlled
linical trials that have intensive oversight and protocol-
riven care. In our study design, we kept the physician
ntervention to a minimum, thereby minimizing any Haw-
horne effect. Beyond requesting a test order and reporting
he laboratory results with interpretation, there was no
urther communication with physicians, and no protocol-
ased constraints on patient care.
Our study includes an intention-to-treat design in which
onth period following initiation of warfarin treatment, including only the events
historical controls). (A) Events due to any cause; (B) events due to bleeding ore 6-m
rvals (e attributed adverse events to the intervention group, even
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ests. This is the most conservative approach to measuring
utcomes, because it overestimates adverse outcomes in the
enotype group and thus biases against the hypothesis that
enotyping improves outcomes. Even in the intention-to-
reat analysis, we noted a 30% decrease in hospitalizations.
Warfarin genotyping does not replace or obviate the need
or routine monitoring of international normalized ratio
INR). Although we did not mandate a specific protocol for
NR measurement in the laboratory report to physicians,
he reports noted that frequent INR measurements might
e indicated, especially with certain genotypes. Our study
id not directly assess the impact of genotyping on the
requency or optimal protocol for INR measurement.
Further research is warranted to replicate and extend our
ndings. Important questions include whether age, indica-
ion, comorbidity, practice setting, and co-medications af-
ect the relative value of genotyping in patients initiating
arfarin treatment. It would also be informative to deter-
ine which adverse events were reduced and in whom. A
reliminary subanalysis suggests that the reductions in
ospitalization were due primarily to reductions in throm-
oemboli. Future clinical effectiveness studies should com-
are new anticoagulants to genetically guided warfarin
reatment regimens.
Our study found that warfarin genotyping lowered the
verall risk of hospitalization, including the risk of hospi-
alization for bleeding or thromboembolism. These lower
ates of adverse events may offset some or all of the cost of
arfarin genotyping. Although an economic analysis is
utside the scope of this report, our data should help to
etermine the net financial cost of paying for genotype
esting as a component of warfarin therapy.
onclusions
arfarin genotyping reduces the risk of hospitalization for
leeding or thromboembolism in patients who initiate
arfarin treatment in outpatient practice settings. These
ffects appear to be large, statistically significant, and clin-
cally meaningful. Clinicians should seriously consider
enotyping their outpatients who are beginning warfarin
reatment.
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